Septerna Inc (SEPN) Actualités

Form 4 - Statement of changes in beneficial ownership of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Septerna Provides Corporate Overview and Reports Fourth Quarter and Full Year 2024 Financial Results

Preclinical Work Advancing with Plans to Select a Next-Generation Oral Small Molecule PTH1R Agonist to...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Septerna to Present at TD Cowen 45th Annual Health Care Conference

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology...

Form 8-K - Current report

Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing...

Form 8-K - Current report

Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a...

Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report